Drug intelligence / Profile preview

Kombi 5V

Development stage: Preclinical
Lead developer: Betuvax
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Kombi 5V is a multivalent recombinant protein vaccine candidate developed by the Human Stem Cells Institute (Artgen) in collaboration with its subsidiary Betuvax. Designed to provide simultaneous protection against both seasonal influenza and COVID-19, the vaccine is built on the Betusfera platform. This platform utilizes recombinant viral antigens combined with a proprietary betulin-based corpuscular adjuvant, which is intended to enhance the immune response while maintaining a favorable safety profile. The '5V' designation likely refers to its pentavalent nature, targeting four influenza strains and the SARS-CoV-2 virus. It is currently in preclinical development.

Other names: Комби 5V

Targets

SARS-CoV-2 spikeHA (Hemagglutinin)

Beyond the preview

Go deeper on Kombi 5V.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kombi 5V.

Explore the full profile